Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

s, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.

Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Rising star Divine Skin Inc. (DSKX), which has been expanding ... long-time leader in the cosmetics industry, to become its president. ... Divine Skin because I believe their innovative products are unmatched ... with a ,wow, factor." A dozen Divine ...
... 25, 2011 For the first time, Eli Lilly and ... to more than 800 grassroots projects across the globe and ... Foundation—doubling the value and impact of each employee,s charitable contribution. ... to offer its employees across the world a customized Lilly ...
... Sciences International, Inc. (Nasdaq: BDSI ) announced ... portion of its Phase 3 clinical trial assessing the ... of moderate to severe chronic pain, signifying completion of ... are very pleased to have brought to completion our ...
Cached Biology Technology:Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 3Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 4BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 3
(Date:7/9/2014)... with the highest distribution in the Iberian Peninsula. It ... comes into contact with the red swamp crayfish, which ... Spaniard Germn Orizaola from the University of Uppsala (Sweden) ... a defensive response to the invasive species. They also ... with the crayfish. , Numerous invasive organisms are currently ...
(Date:7/9/2014)... antagonists can alleviate the symptoms of Alzheimer,s ... dysfunction and effectively scavenge amyloid beta peptide ... vaccines reduced and eliminated Aβ deposition in ... and significantly improved behavioral and cognitive impairment. ... Affiliated Hospital of China Medical University, China ...
(Date:7/9/2014)... it must first make a copy of its DNA, a ... billions of times a day in the human body. While ... cells use to replicate DNAthe enzymes that unzip the double-stranded ... picture of how the process works. , Now, researchers at ... what goes on at the "replication fork"the point where DNA ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4
... With the heart having limited ability to regenerate following injury, ... in the developed world. Research impacting strategies for heart repair ... University of Houston (UH). Eric N. Olson, a ... will present "Heart Making and Heart Breaking: New Strategies for ...
... now a routine part of our nation,s weather forecast. Remarkably ... the Plains states and the West. The year also brought ... unusually warm winter meant little snowfall and bad news for ... events tell us about our changing climate? The Woods ...
... N.Y. A Cornell University scientist and designer from ... at the molecular level with insecticides for warding off ... 655,000 people annually on the continent. Though insecticide-treated ... African homes, the Cornell prototype garment can be worn ...
Cached Biology News:New heart repair strategies discussed at UH lecture May 15 2WHOI to host public forum on climate change and global water supplies 2African scientist, designer partner to fashion anti-malaria garment that wards off bugs 2
... that retain stiffness in liquids, protect against ... on each strip have chemically bonded dyes; ... provide clear comparison. Full-range strips (0 to ... of 100; each strip is approximately 1/4 ...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
... Since the Flp-In System creates isogenic ... equivalent levels of the protein of ... in Figure 3. In this experiment ... (CAT) was subcloned into pcDNA5/FRT and ...
Biology Products: